Skip Navigation LinksHome > June 2010 - Volume 29 - Issue 6 > LONG-TERM EFFICACY AND SAFETY OF FOSAMPRENAVIR IN HUMAN IMMU...
Pediatric Infectious Disease Journal:
doi: 10.1097/INF.0b013e3181d285ac
Brief Reports

LONG-TERM EFFICACY AND SAFETY OF FOSAMPRENAVIR IN HUMAN IMMUNODEFICIENCY VIRUS-INFECTED PEDIATRIC PATIENTS

Palladino, Claudia PhD*; Briz, Verónica PhD*; Policarpo, Sergio Negre MD†; Silveira, Laura Fernandez MD‡; de José, M Isabel MD§; González-Tomé, M Isabel MD¶; Moreno, David MD∥; León Leal, Juan A. MD**; Mellado, M José MD††; de Ory, Santiago J. BSc*; Ramos, José T. MD‡‡; Muñoz-Fernández, M Ángeles PhD, MD*

Supplemental Author Material
Collapse Box

Abstract

Fosamprenavir (FPV) efficacy in human immunodeficiency virus (HIV)-infected pediatric patients is still being evaluated in ongoing clinical trials. The long-term efficacy and safety of FPV boosted with ritonavir (FPV/r) was evaluated in 20 antiretroviral-naive and antiretroviral-experienced HIV-vertically infected pediatric patients. Analyses of CD4+ T-cells, HIV-ribonucleic acid (RNA), and clinical status were performed during a median of 180 weeks. Initially, median HIV-RNA was 4.6 log10 in naive and 4.4 log10 in pretreated patients. Median CD4+ T-cell was 17% and 31%, respectively. After FPV/r treatment, 18 of 20 patients achieved undetectable HIV-RNA and 4 of 20 experienced adverse events. To date, FPV/r treatment has shown sustained antiviral response and immunologic improvement in our 20 patients.

© 2010 Lippincott Williams & Wilkins, Inc.

Login

Article Tools

Share

Article Level Metrics

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.